Skip to main content

Table 2 Clinical and PET/CT characteristics of the patients in the training and testing cohorts

From: 18F-FDG-PET/CT-based machine learning model evaluates indeterminate adrenal nodules in patients with extra-adrenal malignancies

Characteristics

Training cohort (n = 182)

Testing cohort (n = 121)

P+value

 

Total

(n = 182)

ABNs

(n = 85)

AMs

(n = 97)

P value

Total

(n = 121)

ABNs

(n = 53)

AMs

(n = 68)

P value

Age (years)

63[56,68]

64[58;69]

61[56;68]

0.145

62[56;68]

64[58;69]

61[56;67]

0.066

0.954

CTU

32[24;38]

25[19;32]

37[31;40]

 < 0.001*

33[25;38]

25[16;33]

35 [31;41]

 < 0.001*

0.879

SUVmax

3.7[2.7;6.9]

2.9[2.2;3.5]

6.6[3.9;9.0]

 < 0.001*

4.2[2.8;7.0]

2.8[2.4;3.5]

6.5[4.5;9.5.0]

 < 0.001*

0.417

LD (cm)

1.6[1.3;2.0]

1.5[1.2;1.9]

1.7[1.4;2.2]

 < 0.001*

1.6[1.3;2.0]

1.5[1.2;1.8]

1.8[1.4;2.0]

0.004*

0.861

SD (cm)

1.2[1.0;1.6]

1.2[1.0;1.4]

1.2[1.1;1.7]

0.113

1.2[1.0;1.5]

1.2[1.0;1.4]

1.2[1.1;1.5]

0.137

0.376

SUV/liver

1.16[0.876;2.27]

0.968[0.769;1.1]

2.12[1.28;2.91]

 < 0.001*

1.35[0.889;2.15]

0.913[0.781;1.17]

2.07[1.37;3.13]

 < 0.001*

0.504

SUV/spleen

1.40[1.04;2.73]

1.12[0.9;1.29]

2.68[1.6;4]

 < 0.001*

1.54[1.08;2.75]

1.13[0.914;1.35]

2.57[1.77;4.09]

 < 0.001*

0.496

Gender

        

0.280

 Female

79 (43.4%)

51(60%)

28(28.9%)

 < 0.001*

61 (50.4%)

33(62.3%)

28(41.2%)

0.034*

 

 Male

103 (56.6%)

34(40%)

69(71.1%)

 

60 (49.6%)

20(37.7%)

40(58.8%)

  

Lesion location

        

0.623

 Left

125 (68.7%)

60(70.6%)

65(67%)

0.720

79 (65.3%)

38(71.7%)

41(60.3%)

0.265

 

 Right

57 (31.3%)

25(29.4%)

32(33%)

 

42 (34.7%)

15(28.3%)

27(39.7%)

  

Clinical stage

        

0.946

 I and II

47 (25.8%)

39(45.9%)

8(8.2%)

 < 0.001*

30 (24.8%)

20(37.7%)

10(14.7%)

0.007*

 

 III and IV

135 (74.2%)

46(54.1%)

89(91.8%)

 

91 (75.2%)

33(62.3%)

58(85.3%)

  

Primary tumor

        

0.352

Other cancers

71 (39%)

46(54.1%)

25(25.8%)

 < 0.001*

40 (33.1%)

24(45.3%)

16(23.5%)

0.012*

 

Lung cancer

111 (61%)

39(45.9%)

72(74.2%)

 

81 (66.9%)

29(54.7%)

52(76.5%)

  
  1. Categorical variables are presented as n (%), Continuous variables are presented as median (interquartile)
  2. PET/CT positron emission tomography/computed tomography, AMs adrenal metastases, ABNs adrenal benign nodules, CTU the value on unenhanced CT, SUVmax the maximum standardized uptake value, LD long diameter, SD short diameter, SUV/liver the ratio of the adrenal, SUVmax to the mean liver SUV, SUV/spleen the ratio of the adrenal, SUVmax to the mean spleen SUV
  3. *A significant difference between AMs and ABNs in the training or testing cohort
  4. +A significant difference between the training and testing cohorts
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us